VIMAC’s investing model is founded on two core principlesâ€”respect for the entrepreneur, and humble acceptance that nobody has seen the future. New business creation is essentially a collaborative enterprise where success requires continuous learning and broad-based sharing of innovative ideas.
Based in Boston, they deploy capital in early-stage companies located in the eastern U.S. and Canada. Today, they have two separate investment teamsâ€”one focused on early stage ventures in IT/Adv.Materials technologies and the other focused on life sciences.
To date, VIMAC investments have led to the creation of over 20 successful companies that continue to generate business innovations in IT, communications, and Internet technologies. These investments today account for over $2 billion in market value. The fund seeks to make about five new investments each year. A new investment typically goes into a Series A or Series B round with adequate reserves to support subsequent funding until the company exits via a trade sale or an IPO. Over its lifetime, a company is likely to receive $5 million to $15 million from the fund. The life sciences team makes investments from the VIMAC Milestone Medica in early stage biotechnology and medical device companies.
They lead or co-lead most investments and their managers play a very active role on portfolio companiesâ€™ Boards of Directors. Often, they invest in a company’s first institutional round of funding and maintain support throughout the companyâ€™s lifecycle. Along the way, they maintain a close working relationship with the management team, helping them refine business plan, build go-to-market strategies, enhance capital efficiency, find early customers and partners, and grow the business.
|Combinent Biomedical Systems||12/09||Venture Round||$500k||3|
|NeoEdge Networks||6/07||Series B||$3M||2|
|Natural Convergence||11/06||Series C||$10M||7|
|Nakina Systems||4/05||Series B||$10M||4|